OREX rockets higher on Diet Pill news. Orexigen rose $5.20, or 109 percent, to $9.96 at 9:57 a.m. New York time in Nasdaq Stock Market composite trading, the most since April 2007. Options traders placed record bets on Orexigen last week, saying a positive panel vote would double the company’s value. Vivus shares gained $1.20, or 15 percent, to $9 as analysts said the Orexigen recommendation bodes well for the heart risks with Vivus’s drug, Qnexa. Arena jumped 20 cents, or 14 percent, to $1.61 in Nasdaq trading.
About 68 percent of American adults are overweight, raising their risk of diabetes, heart disease, high blood pressure and cancer, according to the 2008 National Health and Nutrition Examination Survey. Almost 34 percent are obese, measured as a ratio between height and weight.
This could easily be a $25+ stock going forward. Marketclub has a very interesting take on how this news affects OREX. They are offering a Free complimentary OREX Stock Analysis sent directly to your in-box not strings attached. Just tap this link and check your e-mail. “Smart Scan Chart Analysis confirms that a strong uptrend is in place and that the market remains positive longer term”
